Analysts Set Expectations for YMAB FY2026 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Research analysts at HC Wainwright issued their FY2026 EPS estimates for shares of Y-mAbs Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst R. Burns expects that the company will post earnings of ($0.92) per share for the year. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.10. The company had revenue of $20.90 million for the quarter, compared to the consensus estimate of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%.

Several other equities research analysts have also recently weighed in on the company. Truist Financial decreased their price target on Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Oppenheimer decreased their price objective on shares of Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 14th. Morgan Stanley decreased their price objective on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, March 5th. Bank of America cut shares of Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price objective on the stock. in a research report on Tuesday, April 22nd. Finally, Wedbush restated an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Two investment analysts have rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $16.60.

Y-mAbs Therapeutics Stock Up 1.7%

Shares of YMAB opened at $4.17 on Tuesday. The business’s 50-day moving average price is $4.45 and its 200-day moving average price is $6.93. Y-mAbs Therapeutics has a twelve month low of $3.55 and a twelve month high of $16.11. The stock has a market cap of $188.83 million, a PE ratio of -7.72 and a beta of 0.53.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of YMAB. Wells Fargo & Company MN lifted its position in Y-mAbs Therapeutics by 54.1% in the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock worth $137,000 after buying an additional 6,131 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Y-mAbs Therapeutics by 10.4% in the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock worth $399,000 after buying an additional 2,854 shares during the last quarter. Geode Capital Management LLC lifted its position in Y-mAbs Therapeutics by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 822,309 shares of the company’s stock worth $6,440,000 after buying an additional 8,820 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Y-mAbs Therapeutics by 1.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company’s stock worth $2,228,000 after buying an additional 4,963 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in Y-mAbs Therapeutics in the fourth quarter worth $46,000. 70.85% of the stock is currently owned by institutional investors.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. This represents a 5.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 22.50% of the stock is currently owned by corporate insiders.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.